
The Coronary Plaque Reimbursement Playbook: Inside Elucid's $55M Raise and the Economics of Non-Invasive Cardiovascular AI
Dr. Dereck Mush, MD, MBAInvestment firm
Patient Square Capital, a health care investment firm, formed Elevage in May 2023 as a portfolio company and committed $300 million to it. Elevage invests in FDA regulated devices, including software as a medical device, diagnostics, lab tools, and health IT and tech enabled services. Michael Wasserman is chief executive, and Patient Square's Jim Momtazee chairs the board. In HTS coverage, Elevage joined Elucid's $55 million Series D in September 2026, alongside IAG Capital Partners, to fund commercial expansion of Elucid's AI software for cardiovascular plaque analysis.
Elevage provides capital and operating support to growth stage medical technology companies to help them reach regulatory approval and commercial scale.
How Elevage Medical Technologies got here, step by step.
2023
Patient Square Capital forms Elevage with a $300 million capital commitment.
Venture fund
Corporate venture
Venture fund
Venture fund
Venture fund
Venture fund

Dr. Dereck Mush, MD, MBAThe HealthTech Signal
The 8 Most Innovative MedTech Devices Right Now
Dr. Dereck Mush, MD, MBA
Dr. Dereck Mush, MD, MBA
Dr. Dereck Mush, MD, MBAKeep exploring
Your daily HealthTech Signal
Get the latest HealthTech news, understand why it matters, and see where the industry is headed.



Read by teams at companies like: